PL1680105T3 - Zastosowanie inhibitorów glukozydazy do leczenia mukowiscydozy - Google Patents
Zastosowanie inhibitorów glukozydazy do leczenia mukowiscydozyInfo
- Publication number
- PL1680105T3 PL1680105T3 PL04805405T PL04805405T PL1680105T3 PL 1680105 T3 PL1680105 T3 PL 1680105T3 PL 04805405 T PL04805405 T PL 04805405T PL 04805405 T PL04805405 T PL 04805405T PL 1680105 T3 PL1680105 T3 PL 1680105T3
- Authority
- PL
- Poland
- Prior art keywords
- mucoviscidosis
- glucosidase inhibitors
- gen
- therapy
- delf508
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Steroid Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0313134A FR2861991B1 (fr) | 2003-11-07 | 2003-11-07 | Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
| EP04805405A EP1680105B1 (fr) | 2003-11-07 | 2004-11-05 | Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
| PCT/FR2004/002858 WO2005046672A2 (fr) | 2003-11-07 | 2004-11-05 | Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1680105T3 true PL1680105T3 (pl) | 2009-07-31 |
Family
ID=34508347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04805405T PL1680105T3 (pl) | 2003-11-07 | 2004-11-05 | Zastosowanie inhibitorów glukozydazy do leczenia mukowiscydozy |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7973054B2 (https=) |
| EP (1) | EP1680105B1 (https=) |
| JP (1) | JP4740868B2 (https=) |
| KR (2) | KR20100038452A (https=) |
| CN (1) | CN100534432C (https=) |
| AT (1) | ATE423561T1 (https=) |
| AU (1) | AU2004289083B2 (https=) |
| BR (1) | BRPI0416228A (https=) |
| CA (1) | CA2545133C (https=) |
| CY (1) | CY1110468T1 (https=) |
| DE (1) | DE602004019674D1 (https=) |
| DK (1) | DK1680105T3 (https=) |
| ES (1) | ES2321725T3 (https=) |
| FR (1) | FR2861991B1 (https=) |
| HR (1) | HRP20090159T1 (https=) |
| IL (1) | IL175453A (https=) |
| NO (1) | NO336904B1 (https=) |
| NZ (1) | NZ547261A (https=) |
| PL (1) | PL1680105T3 (https=) |
| PT (1) | PT1680105E (https=) |
| RU (1) | RU2358725C2 (https=) |
| SI (1) | SI1680105T1 (https=) |
| WO (1) | WO2005046672A2 (https=) |
| ZA (1) | ZA200603726B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3782655A1 (en) | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| DE602007008870D1 (de) * | 2006-04-24 | 2010-10-14 | Amc Amsterdam | Verbessertes verfahren zur behandlung von cystischer fibrose |
| PL2533050T6 (pl) | 2006-05-16 | 2016-05-31 | Amicus Therapeutics Inc | Możliwości leczenia choroby Fabry'ego |
| EP2816113A3 (en) * | 2008-09-11 | 2015-03-25 | Galapagos N.V. | Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator |
| ITFE20080032A1 (it) * | 2008-10-23 | 2010-04-24 | Azienda Ospedaliera Istituti Ospit Alieri Di Vero | Effetto anti infiammatorio del miglustat cellule dell'epitelio bronchiale |
| GB201000499D0 (en) | 2010-01-13 | 2010-03-03 | Fleet George W J | Treatment of cystic fibrosis |
| WO2011095772A2 (en) | 2010-02-04 | 2011-08-11 | Summit Corporation Plc | Novel iminosugar therapeutics |
| GB201006434D0 (en) * | 2010-04-19 | 2010-06-02 | Summit Corp Plc | Novel iminosugar combinations |
| KR20230066482A (ko) | 2012-03-07 | 2023-05-15 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물 |
| JP6456393B2 (ja) * | 2013-09-16 | 2019-01-23 | エマージェント バイロロジー エルエルシー | デオキシノジリマイシン誘導体およびその使用方法 |
| FR3017536B1 (fr) | 2014-02-18 | 2017-05-26 | Univ La Rochelle | Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase |
| CN114540327B (zh) | 2014-09-30 | 2026-03-24 | 阿米库斯治疗学公司 | 具有增强的碳水化合物的高强度酸性α-葡糖苷酶 |
| KR20250007693A (ko) | 2015-12-30 | 2025-01-14 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| AU2017239641A1 (en) | 2016-03-30 | 2018-10-18 | Amicus Therapeutics, Inc. | Formulations comprising recombinant acid alpha-glucosidase |
| CA3019354A1 (en) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Method for selection of high m6p recombinant proteins |
| WO2017187274A1 (en) * | 2016-04-29 | 2017-11-02 | Institut Pasteur | Methods and compositions for modifying cystic fibrosis transmembrane conductance regulator activity |
| US10478427B2 (en) * | 2016-07-07 | 2019-11-19 | National University Corporation Chiba University | Therapeutic agent for fibrosis and inhibitor of nuclear translocation of phosphorylated smad |
| SMT202300187T1 (it) | 2017-05-15 | 2023-07-20 | Amicus Therapeutics Inc | Alfa-glucosidasi acida umana ricombinante |
| PL3630725T3 (pl) * | 2017-06-01 | 2026-03-23 | Idorsia Pharmaceuticals Ltd | Postać krystaliczna n-butylodeoksygalaktonojirymycyny |
| CN108187051A (zh) * | 2018-01-30 | 2018-06-22 | 中国药科大学 | α-L-岩藻糖苷酶及抑制剂用于制备防治心肌缺血损伤的药物的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO154918C (no) * | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
| MY128261A (en) * | 1992-10-27 | 2007-01-31 | Merck Sharp & Dohme | New substituted azetidinones as anti-inflammatory and antidegenerative agents |
| WO1998020123A2 (en) | 1996-11-04 | 1998-05-14 | Institut Curie | Stable cell lines expressing the cftr protein or a mutant of this protein, tool for selecting molecules having an effect on the intracellular transport of these proteins |
| ID21411A (id) * | 1997-12-10 | 1999-06-10 | Takeda Chemical Industries Ltd | Agen untuk mengobati daya tahan glukosa yang berisiko tinggi rusak |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US6476194B1 (en) * | 1999-06-29 | 2002-11-05 | National Research Council Of Canada | Method for folding unfolded proteins |
| AU5799500A (en) * | 1999-06-29 | 2001-01-22 | Mcgill University | Human alpha 1,2-mannosidase |
| AU7398900A (en) * | 1999-09-23 | 2001-04-24 | Hospital For Sick Children, The | Three-dimensional structure and crystal of a class i alpha1,2-mannosidase, and methods of use thereof |
| AU2002359327A1 (en) * | 2001-10-30 | 2003-05-12 | Thomas Jefferson University | Method of treating viral infections |
| US7081260B2 (en) * | 2002-10-29 | 2006-07-25 | Council Of Scientific And Industrial Research | α-Glucosidase inhibitors from a natural source |
| EP2857036B1 (en) * | 2003-01-31 | 2016-12-21 | Mount Sinai School of Medicine of New York University | Combination therapy for treating protein deficiency disorders |
| US7071341B2 (en) * | 2003-02-28 | 2006-07-04 | Council Of Scientific And Industrial Research | α-Glucosidase inhibitors and their synthesis from a natural source |
-
2003
- 2003-11-07 FR FR0313134A patent/FR2861991B1/fr not_active Expired - Fee Related
-
2004
- 2004-11-05 ES ES04805405T patent/ES2321725T3/es not_active Expired - Lifetime
- 2004-11-05 NZ NZ547261A patent/NZ547261A/en not_active IP Right Cessation
- 2004-11-05 KR KR1020107004147A patent/KR20100038452A/ko not_active Withdrawn
- 2004-11-05 EP EP04805405A patent/EP1680105B1/fr not_active Expired - Lifetime
- 2004-11-05 PT PT04805405T patent/PT1680105E/pt unknown
- 2004-11-05 DK DK04805405T patent/DK1680105T3/da active
- 2004-11-05 BR BRPI0416228-5A patent/BRPI0416228A/pt not_active Application Discontinuation
- 2004-11-05 US US10/578,328 patent/US7973054B2/en not_active Expired - Fee Related
- 2004-11-05 ZA ZA200603726A patent/ZA200603726B/en unknown
- 2004-11-05 AT AT04805405T patent/ATE423561T1/de active
- 2004-11-05 AU AU2004289083A patent/AU2004289083B2/en not_active Ceased
- 2004-11-05 HR HR20090159T patent/HRP20090159T1/xx unknown
- 2004-11-05 KR KR1020067010948A patent/KR100979276B1/ko not_active Expired - Fee Related
- 2004-11-05 CA CA2545133A patent/CA2545133C/fr not_active Expired - Fee Related
- 2004-11-05 RU RU2006119914/14A patent/RU2358725C2/ru not_active IP Right Cessation
- 2004-11-05 JP JP2006538890A patent/JP4740868B2/ja not_active Expired - Fee Related
- 2004-11-05 CN CNB2004800382212A patent/CN100534432C/zh not_active Expired - Fee Related
- 2004-11-05 SI SI200431106T patent/SI1680105T1/sl unknown
- 2004-11-05 PL PL04805405T patent/PL1680105T3/pl unknown
- 2004-11-05 DE DE602004019674T patent/DE602004019674D1/de not_active Expired - Lifetime
- 2004-11-05 WO PCT/FR2004/002858 patent/WO2005046672A2/fr not_active Ceased
-
2006
- 2006-05-04 IL IL175453A patent/IL175453A/en active IP Right Grant
- 2006-06-07 NO NO20062617A patent/NO336904B1/no not_active IP Right Cessation
-
2009
- 2009-05-14 CY CY20091100518T patent/CY1110468T1/el unknown
-
2011
- 2011-05-26 US US13/116,482 patent/US8242136B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL175453A0 (en) | Use of glucosidase inhibitors for therapy of mucovisidosis | |
| Ding et al. | What is noise-induced hearing loss? | |
| Rosenthal et al. | Tramadol/acetaminophen combination tablets for the treatment of pain associated with osteoarthritis flare in an elderly patient population | |
| EP1237610A4 (en) | METHOD AND DEVICE FOR SIMULTANEOUS ADMINISTRATION OF VIN GASES AND MEDICATIONS FOR POTENTIALIZING THEIR EFFECT IN HEADACHES, ANGINA AND OTHER Suffering | |
| WO2005107726A3 (en) | Method for the treatment of back pain | |
| CA2375679A1 (en) | Methods and apparatus for relieving headaches, rhinitis and other common ailments | |
| DK1345895T3 (da) | Hidtil ukendt diphenylazetidioner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse til behandling af lipidstofskifteforstyrrelser | |
| MX2007009577A (es) | Metodos para predecir respuesta terapeutica en dermatitis atopica a antagonistas del il-31. | |
| NO20040968L (no) | Opioidagonistpreparater med frigjorbar og sekvestrert antagonist | |
| AU2003206311A1 (en) | Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases | |
| AU2003206310A1 (en) | Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases | |
| AR058892A1 (es) | Metodos para tratar lupus cutaneo con el uso de compuestos de aminoisoindolina | |
| DE60128912D1 (en) | Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika | |
| NO20055136D0 (no) | Farmasoytisk sammensetning som innbeffatter et immunosuppressivt stoff for bruk ved behandling av hudsykdommer | |
| EP1542664A4 (en) | METHOD AND COMPOSITIONS FOR TREATING MACULA AND RETINA DISEASES | |
| EP1605950A4 (en) | NOVEL CHEMICAL ENTITIES AND METHODS OF USE IN THE TREATMENT OF METABOLIC DISORDERS | |
| AU1092602A (en) | Genomes participating in rheumatoid arthritis, method of the diagnosis thereof, method of evaluating the onset possibility thereof, diagnostic kit for detectingthem and therapeutic method and remedies for rheumatoid arthritis | |
| AU2002210926A1 (en) | Genomes participating in rheumatoid arthritis, method of the diagnosis thereof, method of evaluating the onset possibility thereof, diagnostic kit for detecting them and therapeutic method and remedies for rheumatoid arthritis | |
| TW200420290A (en) | Methods for the treatment, prevention and management of macular degeneration | |
| IL162768A0 (en) | Method of treatment of a patient requiring analgesia | |
| NO20044321L (no) | Piperazinyl- eller piperidinylamin-sulfaminsyreamider som inhibitorer av steroid sulfatase | |
| WO2005039497A3 (en) | Methods and compositions comprising thalidomide for treatment of fibromyalgia | |
| IL174594A0 (en) | Educated nkt cells and their uses in the treatment of immune-related disorders | |
| Dong et al. | Different resting methods in improving laypersons hands-only cardiopulmonary resuscitation quality and reducing fatigue: a randomized crossover study | |
| DE60141596D1 (de) | Transdermales system zur verabreichung von loratadin und dessen verwendung |